PIK3CD and neoplasm: Adding the PI3K eganelisib broke the tolerance of the tumor model of 4T1 (breast) and B16 (melanoma) to combination anti-PD-1 and anti-CTLA4 resulting in complete remission of tumors in 30% and 80% of the animals, respectively (33).